Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2015 (2015), Article ID 616787, 4 pages
http://dx.doi.org/10.1155/2015/616787
Case Report

Early-Onset Neutropenia Induced by Rituximab in a Patient with Lupus Nephritis and Hemolytic Anemia

Division of Rheumatology, Department of Medicine, University of Puerto Rico, Medical Sciences Campus, San Juan, PR 00936, USA

Received 8 December 2014; Accepted 26 January 2015

Academic Editor: Graciela S. Alarcon

Copyright © 2015 Mariangelí Arroyo-Ávila et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. Danés, A. Agustí, A. Vallano et al., “Available evidence and outcome of off-label use of rituximab in clinical practice,” European Journal of Clinical Pharmacology, vol. 69, no. 9, pp. 1689–1699, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. J. A. Gómez-Puerta, L. F. Quintana, J. H. Stone, M. Ramos-Casals, and X. Bosch, “B-cell depleting agents for ANCA vasculitides: a new therapeutic approach,” Autoimmunity Reviews, vol. 11, no. 9, pp. 646–652, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Sebastiani, M. G. Anelli, F. Atzeni et al., “Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register,” Joint Bone Spine, vol. 81, no. 6, pp. 508–512, 2014. View at Publisher · View at Google Scholar
  4. B. H. Rovin, R. Furie, K. Latinis et al., “Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab Study.,” Arthritis and rheumatism, vol. 64, no. 4, pp. 1215–1226, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. B. Terrier, Z. Amoura, P. Ravaud et al., “Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French autoimmunity and rituximab registry,” Arthritis and Rheumatism, vol. 62, no. 8, pp. 2458–2466, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Ramos-Casals, M. J. Soto, M. J. Cuadrado, and M. A. Khamashta, “Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases,” Lupus, vol. 18, no. 9, pp. 767–776, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Tesfa, S. Ajeganova, H. Hägglund et al., “Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections,” Arthritis & Rheumatism, vol. 63, no. 8, pp. 2209–2214, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J.-E. Gottenberg, L. Guillevin, O. Lambotte et al., “Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases,” Annals of the Rheumatic Diseases, vol. 64, no. 6, pp. 913–920, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. E. Besada, W. Koldingsnes, and J. Nossent, “Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center,” QJM, vol. 105, no. 6, pp. 545–550, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Larrar, C. Guitton, M. Willems, and B. Bader-Meunier, “Severe hematological side effects following Rituximab therapy in children,” Haematologica, vol. 91, no. 8, supplement, p. ECR36, 2006. View at Google Scholar · View at Scopus
  11. E. Enríquez, J. Borrás-Blasco, A. E. Sirvent, M. Masía, and F. Amorós, “Early onset neutropenia after rituximab in lupus nephritis,” Clinical and Experimental Rheumatology, vol. 25, no. 2, p. 345, 2007. View at Google Scholar · View at Scopus
  12. Z. K. Otrock, R. A. R. Mahfouzd, G. O. Oghlakian, Z. M. Salem, and A. Bazarbachi, “Rituximab-induced acute thrombocytopenia: a report of two cases,” Haematologica, vol. 90, supplement, Article ID ECR23, 2005. View at Google Scholar · View at Scopus
  13. R. Ram, L. Bonstein, A. Gafter-Gvili, I. Ben-Bassat, O. Shpilberg, and P. Raanani, “Rituximab-associated acute thrombocytopenia: an under-diagnosed phenomenon,” The American Journal of Hematology, vol. 84, no. 4, pp. 247–250, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Voog, F. Morschhauser, P. Solal-Céligny, M. C. Benyunes, P. S. Multani, and A. Saunders, “Neutropenia in patients treated with rituximab,” The New England Journal of Medicine, vol. 348, no. 26, pp. 2691–2694, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Weissmann-Brenner, B. Brenner, I. Belyaeva, M. Lahav, and E. Rabizadeh, “Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis,” Medical Science Monitor, vol. 17, no. 11, pp. CS133–CS137, 2011. View at Google Scholar · View at Scopus